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ABSTRACT
Background: Chronic rhinosinusitis (CRS) is characterized by local inflammation of the sinonasal tissues.
CRS patients with nasal polyps and asthma often develop acute exacerbation of sinonasal symptoms after up-
per respiratory tract infections. However, the influence of concomitant asthma on the nasal immune response
to viral infection remains unclear.
Methods: Specimens of nasal polyp and mucosal tissues were obtained from 3 groups of CRS patients (n =
14 per group): 1) patients without asthma (CRS group), 2) patients with aspirin-tolerant asthma (ATA group),
and 3) patients with aspirin-intolerant asthma (AIA group). Nasal fibroblasts isolated from the specimens were
stimulated with poly I:C. CXCL10 expression was analyzed by the quantitative real-time polymerase chain re-
action and enzyme-linked immunoadsorbent assay. Biopsy specimens from CRS patients without asthma were
subjected to immunohistochemistry for detection of T-bet and GATA-3 expression in CD3+ T cells by double la-
beling.
Results: Nasal fibroblasts from the ATA and AIA groups showed significantly enhanced expression of CXCL
10 mRNA and protein after poly I:C stimulation compared with cells from the CRS group and the control group
(normal nasal mucosa). In addition to T helper (Th)2 cells, there was more abundant infiltration of Th1 cells into
tissues from the AIA and ATA groups.
Conclusions: Our findings suggest that CRS associated with asthma may become intractable through the
over-production of CXCL10 in response to viral infection.
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INTRODUCTION
Chronic rhinosinusitis (CRS) is a common chronic
disease worldwide that is treated with medication
(e.g., corticosteroids1 or macrolides2) and by endo-
scopic sinus surgery.3 Although there has been a re-
cent increase in the cure of CRS following the intro-
duction of these treatments,4,5 a substantial number
of patients still have a poor outcome. In CRS patients,
nasal polyps arise from the paranasal sinus mucosa
and prolapse into the nasal cavity, causing persistent
nasal obstruction. We have often found that CRS pa-
tients with nasal polyps and asthma show acute exac-
erbation of nasal symptoms after upper respiratory
tract infection. It has been reported that nasal polyps
and asthma are linked by shared inflammation of the
entire airway mucosa, and particularly by increased
infiltration of eosinophils.6 In addition, mucosal
eosinophilia is frequently associated with more se-
vere disease and with recurrence of polyps after sur-
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Table　1　Clinical characteristics of the four groups
Control CRS ATA AIA
No. 7 14 14 14
Sex (F/M) 1/6 2/12 4/10 7/7
Age (yr), mean 26.75 ± 9.29  44.14 ± 16.08 43.75 ± 14.42 47.17 ± 20.21
Age (yr), range 19-40 20-71 18-65 26-71
Allergic rhinitis 0 (0%) 5 (35.7%) 5 (35.7%) 2 (14.3%)
Total IgE (IU/ml)   96.5 ± 58.48 100.25  ± 142.65 257.91 ± 258.73 232.33 ± 373.03
Peripheral blood eosinophils (%)  3.03 ± 2.49  2.57 ± 1.26 8.33 ± 4.44  13.5 ± 10.82
gery.7 Furthermore, CRS patients with aspirin-
intolerant asthma often have particularly severe
asthma that is associated with rhinorrhea and recur-
rent nasal polyps.8,9 These findings suggest that con-
comitant asthma may contribute to the pathophysiol-
ogy of CRS.
Rhinoviruses are the most common cause of viral
upper respiratory tract infections, being responsible
for up to 50% of all episodes of the common cold.10 Vi-
ral infections have been shown to cause obstruction
of the osteomeatal complex, which is thought to be a
critical step in the development of CRS. Viral dsRNA
and its synthetic analogue (poly I:C) are recognized
by multiple pathways involving toll-like receptor 3
(TLR3), the protein kinase receptor, and two recently
described genes: cytosolic RNA helicases retinoic
acid-inducible gene-I (RIG-I) and melanoma differe-
ntiation-associated gene 5 (MDA5).11 Infection of air-
way epithelial cells leads to release of various pro-
inflammatory mediators, including interleukin (IL)-1,
IL-6, IL-8, interferon-inducible protein of 10 kDa (IP-
10)CXCL10, regulated on activation normal T-cell
expressed (RANTES), granulocyte macrophage-
colony stimulating factor, and eotaxin.12-14 These cy-
tokines and chemokines recruit inflammatory cells,
such as neutrophils, lymphocytes, and eosinophils, to
sites of inflammation, and contribute to the exacerba-
tion of acute and chronic inflammation.
Histologically, fibroblasts are abundant in the
stroma of nasal polyps and are thought to be involved
in the pathogenesis of CRS associated with polyps. Al-
though airway epithelial cells are the main target of
viral infection, several studies have detected rhinovi-
rus in the subepithelial layer by in situ hybridization15
and have shown that human airway fibroblasts are
susceptible to rhinovirus infection.16 In addition, it
has been reported that fibroblasts produce type I in-
terferons (IFNs) and CXCL10 after stimulation with
dsRNA.17,18 CXCL10 targets CXC chemokine recep-
tor 3, leading to activation of natural killer cells and
activated T cells, especially T helper (Th)1 cells.
CXCL10 plays an important role in various Th1-
dominant diseases, such as viral and bacterial infec-
tions, autoimmune diseases, and transplant rejec-
tion.19-21 Thus, fibroblasts may also contribute to the
pathogenesis of such diseases through an influence
on the inflammatory response.22 However, little is
known about the response of fibroblasts to viral infec-
tion in CRS patients with nasal polyps and concomi-
tant asthma.
In this study, we classified CRS patients with nasal
polyps based on the presence or absence of asthma
and investigated CXCL10 expression by nasal fibro-
blasts in response to stimulation by factors associated
with viral infection. In addition, biopsy specimens
from these patients were subjected to immunohisto-
chemistry with double labeling to detect the expres-
sion of T-bet (the master regulator of Th1 responses)
and its antagonist GATA-3 in CD3+ T cells.
METHODS
SUBJECTS
A specimen of nasal polyp mucosa was obtained dur-
ing surgery from 49 patients who had been referred
to Jikei University Hospital for endoscopic sinus sur-
gery (Table 1). Specimens were obtained from 3 dif-
ferent groups of CRS patients: 1) 14 CRS patients who
had nasal polyps without asthma (CRS group), 2) 14
patients who had polyps and aspirin-tolerant asthma
(ATA) (ATA group), and 3) 14 patients with polyps
and aspirin-intolerant asthma (ATA group). We ex-
cluded CRS patients without polyps because our aim
was to investigate the features of polyp tissues in this
disease.23 Specimens from 7 controls were also exam-
ined (middle turbinate mucosa was obtained from 5
patients with non-allergic rhinitis and middle meatus
mucosa was harvested from 2 patients with blowout
fractures). Written informed consent was obtained
from all of the patients prior to enrolment, and this
study was approved by the Ethics Committee of Jikei
University Hospital (reference number: 22-130 6307).
The clinical data of the subjects are summarized in
Table 1. Before endoscopic sinus surgery, each pa-
tient’s serum immunoglobulin E level and peripheral
eosinophil count were measured, and sinus CT scan-
ning was performed.
CLINICAL ASSESSMENT
The diagnosis of CRS was based on typical symptoms
(nasal congestion, dysosmia, etc.) documented in the
medical history, the presence of endoscopically vis-
ible nasal polyps arising from the middle meatus, and
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involvement of the ethmoidal and maxillary sinuses
on CT scans of the paranasal sinuses. The diagnosis
of asthma was made by physicians at the Department
of Pulmonology of Jikei University Hospital, based on
a history of typical symptoms, while AIA was diag-
nosed from a history of exacerbation of asthma, nasal
congestion, andor rhinorrhea after intake of aspirin
or other nonsteroidal anti-inflammatory drugs.
CELL CULTURE
Nasal tissues obtained during endoscopic sinus sur-
gery were chopped into small pieces and fibroblasts
from each specimen were cultured at 37℃ in Dul-
becco’s modified Eagle’s mediumF12 (DMEMF12;
Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine
serum (JRH Biosciences, Lenexa, KS, USA), 100
unitsml of penicillin, and 100 μgml of streptomycin
(Life Technologies, Grand Island, NY, USA) under an
atmosphere of 5% CO2 and humidified air. Nasal fibro-
blasts were used after 3 or 4 passages.
STIMULATION OF NASAL FIBROBLASTS
Nasal fibroblasts were seeded in 6-well and 24-well
culture plates (Becton-Dickinson, Franklin Lakes, NJ,
USA). When the cells had reached 80% confluence,
the culture medium was replaced with DMEMF12
(Life Technologies). Then cells were stimulated with
10 μgml of poly I:C (Life Technologies), 103 units of
IFN-β (PBL InterferonSource, Piscataway, NJ, USA),
10 ngml of IFN-γ (R&D Systems, Minneapolis, MN,
USA), or 10 ngml of TNFα (R&D Systems) for 3
hours before extraction of mRNA and for 24 or 48
hours before harvesting the culture supernatant.
QUANTITATIVE REAL-TIME POLYMERASE CHAIN
REACTION (qRT-PCR) FOR CXCL10 mRNA EX-
PRESSION IN NASAL FIBROBLASTS
Total RNA was isolated by using an RNeasy Mini Kit
that included DNase (Qiagen, Hilden, Germany) and
was transcribed to obtain cDNA by using superscript
II (Life Technologies). Then the quantitative polym-
erase chain reaction (qRT-PCR) was performed with
an ABIPRISM 7700 Sequence Detector System (Ap-
plied Biosystems, Foster City, CA, USA) and SYBR
green PCR master mix (Life Technologies). The
primers were as follows: CXCL10: 5’-TGTCAGTGCT
GCTACTCCACCT-3’ (forward) and 5’-CTGTGTATC
CAAGACAGCAGTCAA-3’ (reverse), GAPDH; 5’-GAA
GGTGAAGGTCGGAGTC-3’ (forward) and 5’-GAAGA
TGGTGATGGGATTTC-3’ (reverse). The level of
CXCL10 mRNA expression was normalized by the av-
erage expression of GAPDH.
ENZYME-LINKED IMMUNOSORBENT ASSAY
(ELISA) FOR CXCL10 PROTEIN
Briefly, 96-well plates (Nunc, Roskilde, Denmark)
were coated with 2.0 μgml of anti-human CXCL10
monoclonal antibody (R&D Systems) overnight at
4℃. Then the plates were washed and blocked with
blocking solution (Boehringer, Mannheim, Ger-
many). After adding a supernatant sample or stan-
dard to the wells, the plates were incubated overnight
at 4℃. After washing with PBS containing 0.05%
Tween 20, 100 ngml of biotinylated polyclonal CXCL
10 antibody was added, and the plates were incubated
for 2 hours at room temperature. Further washing
was done and 100 μl of streptavidin-horseradish per-
oxidase (Life Technologies) was added, after which
the plates were let stand for 20 min at room tempera-
ture. Next, the wells were washed, and TMB (KPL,
Gaithersburg, MD, USA) was added. The reaction
was stopped with 2N H2SO4, and absorbance was
measured at 450 nm with a microtiter ELISA reader
(Model 550; Bio-Rad Laboratories, Hercules, CA,
USA). Data were analyzed with Microplate Manager
Software version 5.2.1 (Bio-Rad Laboratories), and
the CXCL10 concentration in each culture superna-
tant was calculated from standard titration curves by
linear regression analysis.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed with deparaf-
finized 4 μm sections cut from paraffin-embedded na-
sal tissue blocks. The paraffin-embedded sections
and slides were blocked by incubation with 5% diluted
normal donkey serum (Chemicon International, Te-
mecula, CA, USA) for 30 minutes at room tempera-
ture. Then sections were incubated with primary
mouse anti-T-bet polyclonal antibody (R&D Sys-
tems), mouse anti-GATA-3 polyclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and rab-
bit anti-CD3 polyclonal antibody (Abcam, Cambridge,
UK) overnight at 4℃. The secondary antibodies were
Alexa 555-conjugated donkey anti-mouse IgG (Life
Technologies) and Alexa 488-conjugated donkey anti-
rabbit IgG (Life Technologies), and incubation was
done for 30 minutes. After washing with PBS, sec-
tions were incubated for 5 min with 4’,6-diamidino-2-
phenylindole dihydrochloride (Dojindo, Kumamoto,
Japan) and mounted with Permafluor (Beckman
Coulter, Miami, FL, USA). Then the sections were
viewed using a Biorevo BZ-9000 microscope (Key-
ence, Osaka, Japan).
STATISTICAL ANALYSIS
Analyses were performed using a statistical package
(SPSS version 19; IBM, Armonk, NY, USA). All analy-
ses were nonparametric. Between-group comparisons
were performed by the nonparametric Mann-
Whitney’s U-test with Bonferroni correction, and dif-
ferences were considered significant at P < 0.05.
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Fig.　1　CXCL10 mRNA expression in nasal fi broblasts after 
poly I:C stimulation. (a) CXCL10 mRNA expression in nasal 
fi broblasts assessed by qRT-PCR. Cultured fi broblasts were 
stimulated by exposure to poly I:C (10 μg/ml) for 3 hours. 
Copy numbers are expressed as the number of transcripts. 
Results were normalized by the expression of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). (b) CXCL10 
concentrations in the culture supernatant. Cultured nasal fi -
broblasts were stimulated by exposure to poly I: C (10 μg/ml) 
for 24 or 48 hours. Data are shown as the mean ± SEM. *, 
signifi cant difference from medium alone (P < 0.05).
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Fig.　2　CXCL10 mRNA expression in nasal fi broblasts stim-
ulated by cytokines. Cultured fi broblasts were stimulated by 
exposure to IFN-β (103 units), IFN-γ (10 ng/ml), or TNFα (10 
ng/ml) for 3 hours. CXCL10 mRNA expression was assessed 
by qRT-PCR. Data are shown as the mean ± SEM. *, signifi -
cant differences from medium alone (P < 0.05). Copy num-
bers are expressed as the number of transcripts. Results 
were normalized by the expression of GAPDH.
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RESULTS
INCREASED CXCL10 EXPRESSION IN NASAL
FIBROBLASTS FROM THE AIA AND ATA
GROUPS
We measured CXCL10 mRNA expression in nasal fi-
broblasts from 4 groups of subjects (CRS, ATA, AIA,
and control) by qRT-PCR and the results are shown
in Figure 1a. In the absence of stimulation, no CXCL
10 mRNA expression was found in any of the four
groups. In response to stimulation with poly I:C (10
μgml), CXCL10 mRNA expression was increased in
nasal fibroblasts from all four groups. In particular,
CXCL10 mRNA expression was significantly higher
in cells from the ATA group and the AIA group than
in cells from the control group or the CRS group,
while no significant difference was noted between the
ATA and AIA groups.
We also detected CXCL10 protein in the culture su-
pernatant of nasal fibroblasts (Fig. 1b). The concen-
tration of CXCL10 culture supernatant from the ATA
group and the AIA group was significantly higher
than in supernatant from the control group or the
CRS group, and the increase was time-dependent.
These findings were similar to those for CXCL10
mRNA expression.
CXCL10 mRNA EXPRESSION BY NASAL FIBRO-
BLASTS SUBJECTED TO VARIOUS STIMULI
There are two proximal NF-κB recognition sites and
the proximal interferon-stimulated response element
(ISRE) within the promoter region of CXCL10.24 Af-
ter poly I:C stimulation of nasal fibroblasts, TLR-3 and
RIG-I signaling activates two cellular kinases known
as TANK-binding kinase-1 and IkappaB kinase-s,
leading to the activation of IFN regulatory factor-3
(IRF-3) and NF-κB.25-30 IRF-3 can also bind directly to
several DNA-binding motifs, including the ISRE, lead-
ing to the direct induction of interferon-stimulated
genes, such as those for IFN-α and IFN-β.24,31,32
Therefore, we assessed CXCL10 mRNA expression
by nasal fibroblasts after stimulation with IFN-β, IFN-
γ, or TNFα. As shown in Figure 2, CXCL10 mRNA
expression was induced by all three cytokines. In the
control group, CXCL10 mRNA expression was more
CXCL10 in Fibroblasts of Refractory CRS
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strongly induced by IFN-β, which activates the ISRE
pathway, than by IFN-γ or TNFα. In the ATA group,
CXCL10 mRNA expression showed a significantly
greater increase in response to TNFα, which acti-
vates the NF-κB pathway, than in the control group
or the CRS group. On the other hand, in the AIA
group, CXCL10 mRNA expression was significantly
higher than in the CRS group after stimulation with
either TNFα or IFN-β.
ANALYSIS OF CELLS EXPRESSING TRAN-
SCRIPTION FACTORS IN NASAL POLYP TIS-
SUES
T-bet and GATA-3 are known to be the principal tran-
scription factors involved in the differentiation of
type-1 (Th1) and type-2 (Th2) helper T cells, respec-
tively. In order to determine whether Th1 or Th2
cells were increased in nasal polyp tissues, we de-
tected T-bet or GATA-3 and CD3 by double im-
munofluorescence staining. CD3+ cells were re-
stricted to the perivascular and subepithelial regions
of nasal biopsy specimens. Representative double-
stained images of T-bet+CD3+ cells (Th1 cells) and
GATA-3+CD3+ cells (Th2 cells) in nasal biopsy speci-
mens are shown in Figure 3a, b. CD3+ cells were de-
tected in all specimens, but the number of CD3+ cells
was significantly higher in the ATA and AIA groups
than in the control and CRS groups (Fig. 3c). In addi-
tion, the number of T-bet+CD3+ cells and GATA-3+
CD3+ cells was significantly higher in the AIA group
than in the control or CRS groups (Fig. 3d, e). In the
ATA group, the number of T-bet+CD3+ cells and
GATA-3+CD3+ cells was slightly higher than in the
control group or the CRS group (Fig. 3d, e), but there
were no significant differences. Thus, Th1 and Th2
cells were significantly increased in nasal polyp tis-
sues from the AIA group compared with the control,
CRS, and ATA groups.
DISCUSSION
CRS is a heterogeneous and multifactorial disease of
unknown etiology. In CRS patients, inflammation of
the upper and lower airways is well documented, and
epidemiological and pathophysiological links be-
tween CRS with or without nasal polyps, asthma,
andor eosinophilic inflammation have been estab-
lished by recent investigations. It has been shown
that viral infection increases the production of a vari-
ety of proinflammatory cytokines and chemokines by
epithelial cells and fibroblasts, which probably con-
tribute to the exacerbation of airway inflamma-
tion.33,34 In this study, we focused on the susceptibil-
ity to viral infection-related factors of fibroblasts from
CRS patients with asthma (ATA and AIA). We found
that the expression of CXCL10 mRNA by nasal fibro-
blasts from CRS patients with asthma (ATA and AIA)
was significantly upregulated in response to poly I:C
compared with fibroblasts from CRS patients without
asthma or controls. We also observed that both Th1
and Th2 cells were abundant in the nasal polyp tis-
sues from CRS patients with asthma (ATA and AIA).
A previous study revealed that poly I:C significantly
increases the expression of mRNAs for CXCL10,
CCL5, CXCL8, and IL-6 by airway epithelial cells
through TLR3 signaling that is dependent on NF-κB
andor interferon regulatory factor (IRF)-3.35 Poly I:C
has also been shown to dose-dependently induce the
production of CXCL10 by human fibroblasts derived
from diploid skin-muscle.36 However, this is the first
report about upregulation of CXCL10 mRNA and pro-
tein expression in nasal fibroblasts by poly I:C stimu-
lation, and we also showed that the response was sig-
nificantly greater in the ATA and AIA groups. It has
been reported that fibroblasts from different individu-
als display distinctive characteristics that are main-
tained even after prolonged culture, suggesting that
fibroblasts may have a highly stable imprinted pheno-
type.37,38 Our results suggested that viral infection
might initiate an intense inflammatory response with
massive release of CXCL10 from nasal fibroblasts
that are susceptible to viral infection-related factors,
such as the fibroblasts isolated from the ATA and AIA
groups.
We also examined the response of CXCL10 mRNA
expression to IFN-β, IFN-γ, and TNFα, in order to
find key differences from poly I:C signaling, since
poly I:C was reported to activate both the IRF-3 and
NF-κB pathways via TLR-3 or RIG-I.25-30 We showed
that CXCL10 mRNA expression was enhanced by
TNFα in the ATA group, whereas it was significantly
enhanced by both IFN-β and TNFα in the AIA group.
Activation of NF-κB in nasal polyps could be impor-
tant because NF-κB induces the transcription of cy-
tokines, chemokines, and adhesion molecules that
play a major role in the inflammatory process.39 It
was recently reported that IL-1β and TNF-α induce
CXCL10 mRNA expression more rapidly in asthmatic
than nonasthmatic airway smooth muscle cells, with
this response being mediated by the activation of NF-
κB and JNK.40 It has also been reported that TLR3
and MDA5 signaling through a common downstream
intermediate (IRF3) is required for maximal sensing
of rhinovirus dsRNA and is involved in CXCL10 ex-
pression.41 More studies are needed to elucidate the
role of alterations in IRF signaling.
The present study showed that Th1 and Th2 cell in-
filtration of nasal polyp tissues was significantly in-
creased in the AIA group compared with the control,
CRS, and ATA groups. These findings suggested that
migration of Th1 cells into nasal polyps might be in-
duced when CXCL10 is produced by fibroblasts in re-
sponse to viral infection, leading to an excessive Th1-
type response in CRS patients with ATA and AIA. Al-
though there was no significant difference of Th1 and
Th2 cell infiltration between the ATA group and the
CRS group, CXCL10 expression was significantly
Yoshikawa M et al.
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Fig.　3　Results of double immunostaining. (a) Representative double immunostaining of T-bet+CD3+ cells in 
nasal biopsy specimens. Cells were stained with DAPI (blue nuclei), CD3 (green), and T-bet (red). White ar-
rows indicate T-bet+CD3+ cells in the merged image. Inset shows double-labeled T-bet+CD3+ cells marked 
by a square in the merged image. (b) Representative double immunostaining of GATA-3+CD3+ cells in nasal 
biopsy specimens. Cells were stained with DAPI (blue nuclei), CD3 (green), and GATA-3 (red). White arrows 
indicate GATA-3+CD3+ cells in the merged image. (c) CD3+ cells: The number of CD3+ cells was signifi cantly 
higher in the ATA and AIA groups than in the control and CRS groups. (d) T-bet+CD3+ cells: The number of 
T-bet+CD3+ cells was signifi cantly higher in the AIA group than in the control and CRS groups. In the ATA 
group, the number of T-bet+CD3+ cells was also higher than in the control and CRS groups, but the difference 
was not signifi cant. (e) GATA-3+CD3+ cells: The number of GATA-3+CD3+ cells was signifi cantly higher in 
the AIA group than in the control and CRS groups. In the ATA group, the number of GATA-3+CD3+ cells was 
also higher than in the control and CRS groups, but the difference was not signifi cant.
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higher in the former group, which is a finding that
conflicts with our hypothesis. One possibility is that
viral inflammation was not reflected by the changes
in the ATA group. There might be other ways in
which CXCL10 contributes to viral-induced exacerba-
tion of CRS. For instance, CXCL10 upregulates
eosinophil functions such as adhesion and O2 genera-
tion and also increases the release of eosinophil-
derived neurotoxin when eosinophilic infiltration oc-
curs during the exacerbation of asthma.42 CXCL10
also has a prominent role in the worsening of airflow
obstruction and airway inflammation in patients with
acute rhinovirus-induced asthma.34 Some recent stud-
ies have suggested that CXCR3 may be expressed by
human CD25hi FOXP3+ CD4+ Tregs, a T cell subset
with potent immunoregulatory properties,43 which
suggests a paradoxical role for CXCL10. The exact
functional implications of these findings can only be
explained by further investigation.
The pathogenesis of ATA and AIA is different. AIA
is attributable to inhibition of cyclooxygenase by
aspirin-like drugs and does not arise from an allergic
reaction. Biosynthesis of cysteinyl leukotrienes is
also upregulated in patients with AIA.44 However,
both AIA and ATA are associated with eosinophilic si-
nusitis and nasal polyposis. The clinical impact of
ATA and AIA on CRS may be influenced by many fac-
tors, but the differences between ATA and AIA have
not been well documented. Basement membrane hy-
perplasia, goblet cell proliferation, and eosinophil in-
filtration have been reported to be more prominent in
the nasal polyps of asthma patients than in polyps
from patients without asthma.45 Based on our find-
ings in the present study, diseases of the lower air-
ways such as ATA and AIA seem to influence gene
expression in nasal polyp fibroblasts, suggesting that
concomitant lower airway disease is a major reason
why CRS may become refractory to treatment.
In conclusion, we found that CXCL10 expression
was upregulated by Poly I:C stimulation in nasal fi-
broblasts from CRS patients with asthma and this in-
duced Th1 cell infiltration into nasal polyp tissues. Al-
though the mechanism leading to differences of
CXCL10 expression between CRS patients with or
without asthma needs to be clarified, our findings
suggest that CRS associated with asthma may
become intractable due to the overproduction of
CXCL10 in response to viral infection.
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